Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Employees - 4,
CEO - Mr. Gregory Duncan,
Sector - Healthcare,
Country - US,
Market Cap - 7.99M
| Ticker | DWTX |
| Index | - |
| Curent Price | 4.18 |
| Change | 3.21% |
| Market Cap | 7.99M |
| Average Volume | 3.62M |
| Income | -12.86M |
| Sales | 0.00M |
| Book Value/Share | -7.60 |
| Cash/Share | 7.77 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 12 |
| Moving Avg 20days | -35.60% |
| Moving Avg 50days | -46.10% |
| Moving Avg 200days | -17.92% |
| Shares Outstanding | 1.91M |
| Earnings Date | Mar 14 BMO |
| Inst. Ownership | 1.61% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 0.54 |
| Price/FCF | - |
| Quick Ratio | 5.21 |
| Current Ratio | 5.21 |
| Debt/Equity | - |
| Return on Assets | -23.44% |
| Return on Equity | -200.48% |
| Return on Investment | -16.12% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 38.53 |
| BETA(β) | 2.01 |
| From 52week Low | 158.02% |
| From 52week High | -85.72% |
| EPS | -11.17 |
| EPS next Year | -5.98 |
| EPS next Qtr | -3.70 |
| EPS this Year | 17.73% |
| EPS next 5 Year | 32.44% |
| EPS past 5 Year | -10.88% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -57.84% |
| Sales Y/Y | - |
| EPS Q/Q | -339.20% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | -344.52% |
| ATR(14) | 1.30 |
| Perf Week | -30.10% |
| Perf Month | -6.07% |
| Perf Quarter | 67.87% |
| Perf Year | -69.04% |
| Perf YTD | 67.87% |
| Target Price | 30.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer